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Abstract
Background: Previously, we reported that polyploid giant cancer cells (PGCCs) induced by cobalt chloride (CoCl2)
could have generated daughter cells with strong invasiveness and migration capabilities via asymmetric divisions.
This study compared the expression of epithelial-mesenchymal transition (EMT)-related proteins, including E-cadherin,
N-cadherin, and vimentin, between PGCCs and their daughter cells, and control breast cancer cell lines MCF-7 and
MDA-MB-231. The clinicopathological significance of EMT-related protein expression in human breast cancer was
analyzed.
Methods: Western blot was used to compare the expression levels of E-cadherin, N-cadherin, and vimentin in breast
cancer lines MCF-7 and MDA-MB-231, between PGCCs with budding daughter cells and control breast cancer cells.
Furthermore, 167 paraffin-embedded breast tumor tissue samples were analyzed, including samples obtained from
52 patients with primary breast cancer with lymph node metastasis (group I) and their corresponding lymph node
metastatic tumors (group II), 52 patients with primary breast cancer without metastasis (group III), and 11 patients with
benign breast lesions (group IV). The number of PGCCs was compared among these four groups.
Results: The number of PGCCs increased with the malignant grade of breast tumor. Group IIhad the highest number of
PGCCs and the differences among group I, II, III and IV had statistically significance (P =0.000). In addition, the expression
of E-cadherin (P = 0.000), N-cadherin (P = 0.000), and vimentin (P = 0.000) was significantly different among the four
groups. Group II exhibited the highest expression levels of N-cadherin and vimentin and the lowest expression levels
of E-cadherin.
Conclusions: These data suggest that the number of PGCCs and the EMT-related proteins E-cadherin, N-cadherin, and
vimentin may be valuable biomarkers to assess metastasis in patients with breast cancer.
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Background
Breast carcinoma is the most common cancer and the
leading cause of cancer death in women around the
world, accounting for 29 % of total new cancer cases in
women and the most common causes of cancer death
are cancers of the lung and bronchus, breast, and color-
ectum in women in 2015 [1]. Breast cancer is the leading
cause of cancer death in women aged 20 to 59 years [1].
Recurrence and metastasis of breast cancer after surgical
removal of the primary tumor are the leading causes of
death in breast cancer patients, while present anti-tumor
treatment has improved the 5-year survival rate of pa-
tients with breast cancer [2]. Currently, the detailed
mechanisms of metastasis in breast cancer are compli-
cated, and many proteins and signaling pathways are
involved in the process of cancer metastasis.
Recently, we have reported that polyploid giant cancer
cells (PGCCs) induced by cobalt chloride (CoCl2) are a
key contributor to cancer occurrence, development, in-
vasion, metastasis, and chemoresistance [3]. PGCCs are
a special sub-population of cancer cells, and the nuclei
of PGCCs are usually irregular. PGCC nuclei are at least
three times greater in size than regular-sized diploid
tumor cell nuclei [4]. They promote the heterogeneity of
solid tumors and have the properties of cancer stem cells
[5, 6]. However, the detailed mechanisms of PGCC for-
mation and their relationships with tumor initiation and
metastasis are not completely defined. CoCl2 is a hyp-
oxic mimic and can induce the formation of PGCCs by
selectively killing regular diploid cells; flow cytometry
and fluorescence in situ hybridization (FISH) reveal the
presence of multiple copies of DNA in single PGCC [7].
We have successfully isolated, purified, and cultured
PGCCs from 22 cancer cell lines, including HEY, SKOV3,
and MDA-MB-231 [8]. PGCCs express normal and cancer
stem cell markers, and can be induced to differentiate into
other tissues, such as adipose, cartilage, erythrocytes, fibro-
blasts, and bone [3, 4, 9, 10]. In addition, they generate
daughter cells (regular-sized diploid cancer cells) via asym-
metric cell divisions, a process of reductive division known
as depolyploidization [11, 12]. Asymmetric cell division, in-
cluding splitting, budding, and burst-like, usually occurs in
the division of low-level eukaryotes, plants, and viruses [3].
Compared to diploid cancer cells, PGCCs with budding
daughter cells and PGCCs alone express lower levels of
cytokeratin and higher levels of vimentin, indicating that
PGCCs and their budding daughter cells have undergone
epithelial-mesenchymal transition (EMT) [10].
EMT has been found to play an important role in can-
cer development and progression. Cancer initiation and
progression are complicated processes that are regulated
by a variety of cellular and signaling proteins, and often
result from malignant epithelial clones that expand as a
result of activating mutations of oncogenes or inactivating
mutations of tumor suppressor genes. EMT facilitates the
metastasis of several types of human cancer, such as blad-
der cancer, primary liver cancer, and malignant melanoma
[13]. The concept of EMT was first put forward by
Greenberg et al. [14]. Now, more and more evidence
confirms that EMT plays an important role in the process
of cancer metastasis [15]. After epithelial cancer cells
undergo EMT, they lose epithelial characteristics and cell
polarity instead of gaining mesenchymal characteristics,
and highly express EMT markers, including snail, slug,
and Twist [16]. In addition, the epithelial marker, E-
cadherin, and the mesenchymal markers, N-cadherin and
vimentin, are regarded as important markers of EMT
[17–19], and are widely used in invasion and metasta-
sis cancer research. It is reported that many cancer
cells exhibit decreased expression of E-cadherin and
increased expression of N-cadherin and vimentin,
which are significantly correlated with the malignant
degree of cancers and the metastasis of cancers to the
lymph nodes. These alterations are in agreement with
the EMT phenotype reported in breast cancer [19,
20] and esophageal squamous cell carcinoma [21].
PGCCs and their budding daughter cells gain strong
invasiveness and migration ability after they undergo
EMT. This study compared the expression of EMT-
related proteins between PGCCs with budding daughter
cells and control cells without CoCl2 treatment. We also
determined the clinicopathological significance of EMT-
related protein expression and the number of PGCCs in
breast cancer.
Methods
Cancer cell lines and culture
The human breast cancer cell lines MCF-7 and MDA-
MB-231 were obtained from the American Type Culture
Collection (ATCC; Manassas, VA, USA). MCF-7 cells
were maintained in complete ATCC-formulated RPMI-
1640 medium (HyClone, Logan, UT, USA), and MDA-
MB-231 cells were grown in ATCC-formulated Leibovitz's
L-15 medium (Gibco, Norwalk, CT, USA), supplemented
with 10 % fetal bovine serum (FBS; ExCell Bio, Shanghai,
China), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin. Cells were routinely incubated at 37 °C and 5 %
CO2 under a humidified atmosphere.
Formation of PGCCs
MCF-7 and MDA-MB-231 cells were cultured in
complete medium in T25 flasks until they reached 80–
90 % confluence. The cells were cultured with different
concentrations of CoCl2 (Sigma-Aldrich, St. Louis, MO,
USA) for different periods based on their hypoxia-
resistance ability. MCF-7 cells were treated with 450 μM
CoCl2 for 72 h, and MDA-MB-231 cells were cultured
with 300 μM CoCl2 for 72 h. The cells were then
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cultured in regular complete medium after being rinsed
with phosphate-buffered saline (PBS). The majority of
regular-sized cells died following treatment with CoCl2,
and only scattered PGCCs survived CoCl2 treatment.
Ten to 15 days after removal of CoCl2, the surviving
PGCCs started to generate daughter cells via budding.
After three or four additional CoCl2 treatments (to ac-
quire a sufficient number of PGCCs), the PGCCs cul-
tured in complete medium with newly budding daughter
cells (approximately 30 % PGCCs with 70 % budding
daughter cells) were used for western blots and later
analysis.
Cell cycle analysis
Cells (0.5 × 106-1 × 106) were collected by trypsinization
and washing in cold PBS twice. Ice-cold 75 % ethanol
was slowly added to cells while vortexing gently, and
cells were fixed overnight at 4 °C. Then, the cells were
rinsed with cold PBS three times, centrifuged at 1000 rpm/
min for 5 min, and resuspended in 200–500 μL cold PBS.
Next, the cell suspension was incubated with 20 μL RNase
A (BestBio, Shanghai, China) for 30 min at 37 °C, and then
with 400 μL propidium iodide (BestBio) for 30 min at 4 °C
in a dark room. Analyses and measurements were per-
formed on an FACSVerse (BD Biosciences, Franklin Lakes,
NJ, USA) flow cytometer at the excitation wavelength of
488 nm.
Western blot analysis
PGCCs (30 %) of MCF-7 and MDA-MB-231 after CoCl2
treatment with budding daughter cells (70 %), and control
cells without CoCl2 treatment were lysed for 30 min on
ice with 100–200 μL ice-cold radio-immunoprecipitation
assay (RIPA) lysis buffer, and centrifuged at 12,000 rpm/
min for 30 min at 4 °C. Protein concentration was
determined, and protein were separated on a 10 % sodium
dodecyl sulfate (SDS) polyacrylamide gel and transferred
to a polyvinylidene fluoride (PVDF) membrane (Beyotime,
Haimen, China). After blocking with 5 % nonfat milk
in 1× Tris-buffered saline with 0.05 % Tween-20 for
3 h at 20–25 °C, the membranes were incubated with
rabbit anti-E-cadherin polyclonal (1:300 dilution; BIOSS,
Woburn, MA, USA), rabbit anti-N-cadherin polyclonal
(1:300 dilution; BIOSS), rabbit anti-vimentin polyclonal
(1:300 dilution; BIOSS), and mouse anti-β-actin monoclo-
nal (1:800 dilution; Zhongshan Inc., Beijing, China) anti-
bodies overnight at 4 °C. Membranes were then incubated
with the appropriate dilution of secondary antibodies at
20–25 °C for 2 h. SuperSignal West Femto Substrate (ECL
detection kit, Thermo Scientific, Norwalk, CT, USA) was
used to detect protein expression. Images were captured
on a film processor and the optical density of each protein
band detected was analyzed with Image-J software. All
western blot experiments were repeated multiple times,
with β-actin being used as a protein-loading control.
Cell migration assay
The migration of control and CoCl2-treated MCF-7 and
MDA-MB-231 PGCCs with their budding daughter cells
was detected using wound-scratch and transwell migra-
tion assays. Cells (1 × 105 cells per well) were seeded in
triplicate into 6-well plates and cultured for 24–48 h
until they reached an appropriate level of confluence.
The wound-scratch assay was performed by uniformly
scratching the monolayer of cells with sterile pipette
tips, and the cells were washed three times with PBS.
Then, serum-free medium was added in place of
complete medium. Cell migration was photographed
and measured in several pre-marked areas at 0 h, 24 h,
and 48 h. Here, the cell migration area was measured
between dashed regions by Image-J software and nor-
malized to the control cells. The wound-healing index
was calculated using the following formula: [(the wound
area at 0 h) – (the wound area at indicated time)]/(the
wound area at 0 h).
The transwell migration assay was performed using
cell culture inserts (8 μm; BD-Falcon, Franklin Lakes,
NJ, USA) inserted into a 24-well plate. Cells (5 × 104
cells per insert) in 100 μL fresh medium with 1 % FBS
were added to the upper chamber, while growth medium
with 20 % FBS was added to the lower chamber. Plates
were then incubated for 20–24 h at 37 °C. After remov-
ing the non-migrated cells and medium in the upper
chamber, the migrated cells retained on the lower side of
the membranes were fixed with 95 % methanol for
10 min and stained with 0.1 % crystal violet for 30 min.
Photos were obtained at × 100 magnification, and cells
were counted in at least three different areas. Three in-
dependent experiments were performed.
Cell invasion assay
Invasion by control and CoCl2-treated MCF-7 and
MDA-MB-231 cells was measured using transwell inva-
sion assays. Cells (5 × 105 per well) were seeded in
100 μL medium with 1 % FBS onto inserts pre-coated
with BD Matrigel Basement Membrane Matrix (BD
Biosciences). Growth medium, with 20 % FBS as the
chemoattractant, was added to the bottom chamber, and
plates were incubated for 24–36 h at 37 °C. After the
medium and non-invaded cells in the upper chamber
were removed, the transwell inserts were fixed with 95 %
methanol for 10 min and stained with 0.1 % crystal vio-
let for 30 min. Photos were taken at × 100 magnification,
and the number of invaded cells was counted in multiple
different fields. Three independent experiments were
performed.
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Tissue samples
Paraffin-embedded human breast tumor tissue samples
(n = 167) were obtained from The First Affiliated Hos-
pital of Anhui Medical University (Hefei, China) be-
tween 2011 and 2012. None of the patients had received
treatment before surgical removal of the tumor. Two
pathologists verified the diagnoses of breast tumors.
These 167 cases of breast tumors were divided into four
groups: 52 cases of primary breast cancer with lymph
node metastasis (group I), and their corresponding
metastatic lymph nodes (group II); 52 cases of primary
breast cancer without metastasis (group III); and 11
cases of benign breast tumors, including breast fibro-
adenoma and mammary gland disease (group IV). The
detail information of patients in group I and group III
including the ER/PR expression, lymph node metastasis
and Ki-67 expression lists in Additional file 1: Table S1.
The agreement for use of these tissue samples was ap-
proved by the Biomedical Ethics Committee of Anhui
Medical University, and the confidentiality of patient in-
formation was maintained.
PGCC definition and counting
PGCC are defined as cancer cells with a nucleus that is
at least three times larger than that of a diploid cancer
cell, as described by Zhang et al. [3]. PGCCs are not
always evenly distributed throughout the sections, and
the number of PGCCs in the hot spots was counted.
For each case, five microscopic hot fields were counted
at × 400 magnification, and the average number was
calculated.
Feulgen staining and ploidy verification
First, 4-μm sections were deparaffinized and dehydrated
with xylene and ethanol. Second, the sections were hy-
drolyzed with 5 M HCl for 50 min at room temperature
(setting for 25 – 30 °C). Third, sections were washed
with 1 M HCl followed by distilled water. Finally, sec-
tions were stained in Schiff ’s reagent for 60 min at room
temperature, which was followed by dehydration of the
sections with ethanol and xylene, and mounting with a
resinous membrane.
For ploidy verification of PGCC, we used the imaging
analysis software (Image-Pro Plus, Version 6.0.0.260;
Media Cybernetics, Inc., Rockville, MD, USA). After
Feulgen staining, typical images under the same condi-
tions of PGCCs and control breast epithelial cells were
captured. After viewing the image and choosing the area
of control breast epithelial cell distribution, the software
was used to calculate the area and integrated optical
density (IOD). Then, we computed the mean optical
density (MOD) of control breast epithelial cells. Simi-
larly, we used the software to determine the MOD of
PGCCs, and then we compared the ratio of MOD of
PGCCs to that of control breast epithelial cells.
Immunohistochemical (IHC) staining
All 4-μm-thick sections were subjected to two-step im-
munohistochemical (IHC) staining. Briefly, the sections
were deparaffinized in xylene, and dehydrated in a set of
graded ethanol solutions. Then, antigen retrieval was
carried out by heating in 0.01 M citrate buffer solution
(pH 6.0) with an autoclave at 120 °C for 5 min [22].
After endogenous peroxidase activity was blocked, the
slides were incubated with the primary antigens over-
night at 4 °C, including mouse anti-E-cadherin monoclo-
nal antibody (MAB-0589; Maixin Bio, Fuzhou, China,
1:200 dilution), mouse anti-N-cadherin monoclonal anti-
body (ZM-0094; Zhongshan Inc., China, 1:100 dilution),
and mouse anti-pig vimentin monoclonal antibody
(kit-0019, ZM-0094; Maixin Bio, Fuzhou, China, 1:200 di-
lution), Slides were then washed three times with PBS for
5 min. Next, the sections were incubated with horseradish
peroxidase-conjugated secondary antibody, rinsed another
three times with PBS for 5 min, incubated with 3, 3'-di-
aminobenzidine (DAB, Zhongshan Inc.) for 1–3 min, and
finally counterstained with hematoxylin. Known positive
samples were used as positive controls, while the negative
controls were run simultaneously by replacing the primary
antibody with PBS.
IHC scoring and quantification
Slide assessment was independently carried out by
two experienced pathologists. In the evaluation of
E-cadherin, N-cadherin, and vimentin expression,
brown-yellow staining in the cytomembrane and/or
cytoplasm was considered positive for expression. Ex-
pression within the tissue sections was quantified ac-
cording to the staining intensity and percentage of
positive cells. The staining intensity was scored as fol-
lows: 0, negative (no staining); 1, weak positive (faint
yellow staining); 2, moderate positive (brownish-yel-
low staining); and 3, strong positive (brown staining).
The number of positive cells was visually evaluated
and stratified as follows: 0 (negative), <5 % positive
cells; 1 (weak), 6 %-25 % positive cells; 2 (moderate),
26 %-50 % positive cells; 3 (above moderate), 51 %-
75 %; and 4 (strong), >76 % positive cells [21]. The
sum of the staining intensity and positive cell scores
was used to determine the staining index for each
section [23].
Statistical analysis
Statistical software SPSS 17.0 for Windows was used to
analyze all the statistical data in this study. All histogram
data are presented as mean ± SD, and all table data are
presented as mean ± SEM. The Kruskal-Wallis test was







Fig. 1 PGCCs with budding daughter cells in MCF-7 and MDA-MB-231 cells. A. MCF-7 PGCCs and control MCF-7 cells. a. Control MCF-7 cells
(×400). b. MCF-7 PGCCs induced by 450 μM CoCl2 treatment for 72 h (×400). Small black arrowheads indicate budded daughter cells; large black
arrow heads indicate PGCCs. c. PGCCs generated daughter cells via budding 10–15 days after CoCl2 treatment. Black arrowheads indicate budded
daughter cells (×100). d. Fast reproduction of PGCCs by generated daughter cells via budding (×100). B. MDA-MB-231 PGCCs and control MDA-MB-231
cells. a. Control MDA-MB-231 cells (×400). b. MDA-MB-231 PGCCs induced by 300 μM CoCl2 treatment for 72 h (×400). Small black arrowheads indicate
budded daughter cells; large black arrowheads indicate PGCCs. c. PGCCs generated daughter cells via budding 10–15 days after CoCl2 treatment. Small
black arrowheads indicate budded daughter cells; large black arrowheads indicate PGCCs (×100). d. Recovery of PGCCs by generated





Fig. 2 Alteration of cell cycle in breast cancer cell lines after CoCl2 treatment. Clear alteration of the cell cycle as analyzed by flow cytometry
was observed in MCF-7 (a) and MDA-MB-231 (c) cells treated with CoCl2. The bar graphs in (b) and (d) depict the relative changes to
cell percentage in different phases of the cell cycle in PGCCs with budding compared to that of control cells. All data represent the
mean ± SD of three independent cultures
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performed to compare the differences in PGCC number
and EMT-related protein expression among the four
groups. The Mann–Whitney test was used to analyze
the differences in PGCC number and EMT-related pro-
tein expression between two groups of the four. Other
comparisons were performed with a two-tailed Student’s
t-test. Here, a p-value < 0.05 was considered statistically
significant.
Results
CoCl2-induced PGCC formation in breast cancer cells
When the breast cancer cell lines MCF-7 and MDA-
MB-231 were treated with high concentrations of CoCl2
over a long period, normal-sized diploid cancer cells
were selectively killed while some large cells with giant
nuclei (PGCCs) survived. After a high concentration
CoCl2 treatment (450 μM) of MCF-7 cells for 72 h killed
most diploid cells, PGCCs could be observed after
removal of floating dead cells, in contrast to the control
MCF-7 cells (Fig. 1A-a and A-b). Similar morphological
changes were observed for the MDA-MB-231 breast
cancer cell line (Fig. 1B-a and B-b). At 10–15 days post-
CoCl2 treatment, the surviving PGCCs cultured in
complete medium generated daughter cells via budding
(Fig. 1A-c and B-c). The number of regular-sized daugh-
ter cells increased from 60 % to 70 % after 24 h of con-
tinuous culture in complete medium, while the
percentage of PGCCs in the flask decreased from 40 %
to 30 % (Fig. 1A-d and B-d). These PGCCs with budding
cells and control cells were used for the cell cycle and
EMT-related protein expression analyses.
Cell cycle analysis in breast cancer cells before and after
CoCl2 treatment
CoCl2-induced alterations to the cell cycle in various
phases in MCF-7 and MDA-MB-231 cells was observed
A
B
Fig. 3 E-cadherin, N-cadherin, and vimentin expression in PGCCs with budding and control MCF-7 and MDA-MB-231 cells. a Western blot was
used to detect differences in E-cadherin, N-cadherin, and vimentin expression in MCF-7 and MDA-MB-231 cells before and after CoCl2 treatment.
b Quantitative results of protein expression differences are shown as histograms. The corresponding densitometric analyses of the
protein bands performed using Image-J software were normalized to the signal of β-actin. Each bar represents the mean ± SD of
three independent experiments (*p < 0.05)
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using flow cytometry (Fig. 2a and c). We observed a
sharp decrease in the number of CoCl2-treated cells in
G1 phase, but an increase in the number of cells in S
and G2 phases (Fig. 2b and d). In addition, flow cyto-
metric analysis confirmed that cells treated with CoCl2
generated a cell subpopulation corresponding to PGCCs,
which had a large increase in DNA copy number.
EMT-related protein expression in control breast cancer
cells and PGCCs with budding
The expression of EMT-related proteins, including E-
cadherin, N-cadherin, and vimentin, was analyzed in
control MCF-7 and MDA-MB-231 cells and in PGCCs
with budding cells. Western blot analysis revealed that
E-cadherin expression was lower in PGCCs with bud-
ding than in control cells, and that expression of N-
cadherin and vimentin was greater in PGCCs with
budding than in control cells (Fig. 3a). A quantitative
analysis of EMT-related protein expression in PGCCs
with budding and control cells is depicted in Fig. 3b.
The densitometric analyses of each protein band were
normalized to the corresponding β-actin band, which re-
vealed a significant difference between PGCCs with bud-
ding and control cells.
Daughter cells budded by PGCCs have great migration
and invasion abilities
To determine whether CoCl2 treatment affects cell
migration in the breast cancer cell lines MCF-7 and
MDA-MB-231, a wound-healing assay was performed
on PGCCs with budding and control cells. Fig. 4a and c
depict the wound-scratch assay at 0 h, 24 h, and 48 h.
The spaces between the red dashed lines gradually nar-
rowed in the panels. The quantitative analysis reveals a
A B
DC
E F G H
Fig. 4 CoCl2 increases the migration and invasion of breast cancer cells. a Representative images of the wound-healing assay for MCF-7 cells at
different times (×40). b MCF-7 cell migration is shown as a wound-healing index quantified by measuring at least three different wound areas. c
Representative images of the wound-healing assay for MDA-MB-231 cells at different times (×40). d Quantitative data of MDA-MB-231 cell migration
between control cells and PGCCs with budding. e, g Transwell migration and invasion assays were performed in control MCF-7 and MDA-MB-231 cells
and PGCCs with budding (×100). Upper panels indicate the migration and lower panels show cell invasion. f, h Quantitative results of transwell migration
and invasion assay in MCF-7 and MDA-MB-231 cells
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significant increase in the cell migration ability of
PGCCs with budding (Fig. 4b and d). Moreover, we also
performed a transwell migration assay with MCF-7
and MDA-MB-231 cells to compare PGCCs with bud-
ding and control cells. As shown in Fig. 4e and g, the
number of migrated cells increased in PGCCs with
budding cells compared with the control cells. To
examine whether CoCl2 treatment affects cell invasion
in MCF-7 and MDA-MB-231 cells, the cell invasion
assay was performed using matrigel-coated transwell
inserts. Invaded cell numbers also greatly increased in
the group of PGCCs with budding cells compared to
control cells (Fig. 4e and g). Quantitative results of
transwell migration and invasion assays in MCF-7
and MDA-MB-231 cells indicated significant differ-
ences in the numbers of migratory and invasive cells
(Fig. 4f and h).
Clinicopathological significance of the number of PGCCs
in human breast tumors
Using the description of PGCCs set by Zhang et al. [3],
we observed morphologically that PGCCs with giant or
multiple nuclei were significantly present in human
breast tumors of group I, group II, and group III (Fig. 5).
As shown in Table 1, group II had the highest number
of PGCCs and group III had the lowest; the difference
between these groups was statistically significant (P =
0.000). PGCCs were not observed in group IV. The aver-
age number of PGCCs was higher in group II than in
group I (Z = −7.402, P = 0.000), higher in group I than in
group III (Z = −6.278, P = 0.000), and higher in group III
than in group IV (Z = −5.196, P = 0.000).
Feulgen staining and mean optical density determination
To observe the nuclei morphologies of PGCCs in human
breast tumor tissues, we performed Feulgen staining.
Feulgen staining, in which DNA is dyed purple, revealed
the distribution of DNA in tumor cells (Fig. 6a). The im-
ages were captured at × 200 magnification, analyzed by
Image-Pro Plus software, and the MOD of control breast
epithelial cells and PGCCs was calculated. Three further
images of normal breast tissue and breast cancer were
obtained and analyzed. By analyzing these images, we
determined an average optical density value for normal
breast epithelium, fluctuating between 14 and 19, and
determined the MOD of PGCCs to be in the range of 40
to 90, positively correlating with the volume of PGCCs.
The ratio of PGCC and control breast epithelial cell ap-
proximations was an integer greater than or equal to 2.
Compared with normal diploid mammary epithelial
cells, the polyploidy nature of PGCCs human breast
tumor tissue was confirmed. Quantitative results of
MOD determinations are shown in Fig. 6b.
Expression of EMT-related proteins in human breast
tumor tissues
To detect the expression level of EMT-related proteins
and their clinicopathological significance, IHC staining
for E-cadherin, N-cadherin, and vimentin was performed
on 167 cases of formalin-fixed, paraffin-embedded hu-
man breast tumor tissues. Positive E-cadherin (Fig. 7a)
staining appeared in the cytomembrane or cytoplasm of
tumor cells, positive N-cadherin (Fig. 7b) staining was
detected in the cytomembrane, and positive vimentin
staining was present in the cytoplasm (Fig. 7c). E-
cadherin (P = 0.000), N-cadherin (P = 0.000), and vimen-
tin (P = 0.000) staining indexes were significantly differ-
ent between the four groups (Table 2). Metastatic cancer
(group II) exhibited the highest N-cadherin and vimen-
tin expression, and the lowest E-cadherin expression
(Fig. 7 and Table 2). Benign breast tumors (group IV)
had the highest E-cadherin expression, and the lowest
Fig. 5 PGCCs in human breast tumors. a PGCCs in primary breast
cancer with metastasis (group I; black arrowheads, H&E, ×400). b
PGCCs in metastatic tumors (group II; black arrowheads, H&E, ×400).
c PGCCs in primary breast cancer without metastasis (group III; black
arrowheads, H&E, ×400). d PGCCs are absent in benign breast
tumors (group IV; H&E, ×400)
Table 1 Comparison of the average number of PGCCs in
human breast tumors







I 52 22.62 ± 1.15 125.193 0.000
Corresponding
metastatic tumor
II 52 41.04 ± 1.49
Primary breast cancer
without metastasis
III 52 11.35 ± 0.90
Benign breast tumor IV 11 0
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Fig. 7 Expression of E-cadherin, N-cadherin, and vimentin in human breast tumor tissues. A. E-cadherin expression in (a) primary breast cancer
with lymph node metastasis (group I), (b) corresponding metastatic cancer (group II), (c) primary breast cancer without metastasis (group III),
and (d) benign breast tumor (group IV) (×200). B. N-cadherin expression in (a) primary breast cancer with lymph node metastasis (group I), (b)
corresponding metastatic tumor (group II), (c) primary breast cancer without metastasis (group III), and (d) benign breast tumor (group IV) (×200).
C. Vimentin expression in (a) primary breast cancer with lymph node metastasis (group I), (b) corresponding metastatic tumor (group II), (c) primary
breast cancer without metastasis (group III), and (d) benign breast tumor (group IV) (×200)
Fig. 6 Feulgen staining and MOD determination of PGCCs and control mammary epithelial cells. A. Feulgen staining between PGCCs and control
mammary epithelial cells. a. Feulgen staining of mammary epithelial cells (black arrowheads, ×200). b. Feulgen staining of PGCCs in breast cancer
(black arrowheads, ×200). B. Quantitative results of MOD determination in PGCCs and control mammary epithelial cells
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N-cadherin and vimentin expression (Fig. 7 and Table 2).
Statistical analysis revealed that the expression of N-
cadherin and vimentin was higher in group II than in
group I (Z = −2.856, P = 0.004; Z = −2.347, P = 0.019; re-
spectively; Table 3), higher in group I than in group III
(Z = −2.736, P = 0.006; Z = −3.545, P = 0.000; respectively;
Table 4), and higher in group III than in group IV (Z = −
1.592, P = 0.111; Z = −2.524, P = 0.012; respectively;
Table 5). The staining indices of N-cadherin and vimen-
tin were significantly different between group I and
group II and between group I and group III. Moreover,
the expression of E-cadherin was lower in group II than
in group I (Z = −2.713, P = 0.007; Table 3), lower in
group I than in group III (Z = −2.720, P = 0.007; Table 4),
and lower in group III than in group IV (Z = −1.246, P =
0.213; Table 5). The differences in E-cadherin expression
were statistically significant between group I and group
II, and between group I and group III. Furthermore,
PGCCs in group I (Fig. 8 –a) and group III (Fig. 8 -e)
undergo EMT and IHC staining for E-cadherin, N-
cadherin and vimentin in group I (Fig. 8 –b,-c,-d) and
group III (Fig. 8 –f,-g,-h) were performed. Results of
IHC staining showed that single stroma PGCC located
in the invasive front of primary breast cancer with me-
tastasis were strong positive for N-cadherin (Fig. 8 -c)
and vimentin (Fig. 8 -d) and weak positive for E-
cadherin (Fig. 8 -b). Single stroma PGCC in group III
had the similar expression of N-cadherin (Fig. 8 -g),
vimentin (Fig. 8 -h) and E-cadherin (Fig. 8 -e) as it in
primary breast cancer with metastasis.
Discussion
PGCCs are large and contain single giant nuclei or mul-
tiple nuclei and are a special sub-population of cancer
cells that contribute to solid tumor heterogeneity.
PGCCs are the most commonly described histopatho-
logic features of human tumors, particularly in high-
grade and advanced-stage tumors, and usually correlate
with poor prognosis (ref ) (Malpica et al., 2004; Polyak,
2011; Wolberg et al., 1999). PGCCs have been consid-
ered as senescent cells, or as at the stage of mitotic ca-
tastrophe, but our previous data revealed that these
large cancer cells were actually live and could generate
daughter cancer cells via budding [3, 4]. PGCCs were
initially observed in flasks after high concentrations of
CoCl2 treatment, which selectively killed regular diploid
cells of HEY, SKOV3, and MDA-MB-231 cancer cells
[3]. CoCl2 can induce the formation of PGCCs through
endoreduplication or cell fusion, and PGCCs can gener-
ate daughter cancer cells via asymmetric cell division, in-
cluding splitting, budding, and burst, which commonly
appears in lower organisms [3, 9, 10]. The daughter cells
generated by PGCCs exhibit mesenchymal phenotypes,
and have stronger migration and invasion abilities than
those of regular diploid cancer cells. In this paper, we
characterized a PGCC as a cancer cell with a nucleus at
least three times larger than that of a diploid cancer cell.
Recently, more studies have confirmed that EMT plays
an important role in tumor invasion and metastasis [24–
26]. In the present study, we investigated the expression
of three EMT-related proteins, including E-cadherin, N-
cadherin, and vimentin, in PGCCs with budding
daughter cells and control cancer cells without CoCl2
treatment. Furthermore, the expression of these pro-
teins was compared in human breast tumor tissues,
and IHC staining showed that expression of these
proteins was associated with breast tumor lymph
node metastasis.
Table 2 The differences of E-cadherin, N-cadherin, and vimentin
expression in human breast tumors












III 52 10.90 ± 0.26 0.46 ± 0.12 0.92 ± 0.15
Benign breast
tumor
IV 11 11.64 ± 0.36 0.09 ± 0.09 0.18 ± 0.12
χ2 35.267 31.455 45.777
P 0.000 0.000 0.000
Table 3 The differences of E-cadherin, N-cadherin, and vimentin
expression between group I and group II




I 52 9.67 ± 0.34 0.96 ± 0.19 1.96 ± 0.24
Corresponding
metastatic tumor
II 52 8.38 ± 0.34 1.81 ± 0.28 3.02 ± 0.35
Z −2.713 −2.856 −2.347
P 0.007 0.004 0.019
Table 4 The differences of E-cadherin, N-cadherin, and vimentin
expression between group I and group III








III 52 10.90 ± 0.26 0.46 ± 0.12 0.92 ± 0.15
Z −2.720 −2.736 −3.545
P 0.007 0.006 0.000
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E-cadherin, a calcium-dependent single-span trans-
membrane glycoprotein, has been widely known as a
tumor suppressor and a characterized molecular marker
of EMT [27], and is an important epithelial cell adhesion
molecule and signal transduction factor located in the
epithelial tissue [25]. The cytoplasmic domain of E-
cadherin interacts with many proteins, including three
catenins (α, β, and p120), and combines with the actin
cytoskeleton. E-cadherin sets up close alloantigen inter-
actions with contiguous E-cadherin molecules in neigh-
boring cells to form the core of the epithelial adherens
junction [28, 29]. Loss of E-cadherin can lead to en-
hanced tumor mobility and invasion [30, 31].
N-cadherin is also a calcium-dependent glycoprotein.
Unlike E-cadherin, N-cadherin is absent in normal epi-
thelium, and promotes a dynamic adhesion state in
tumor cells, allowing not only the separation of single
cells from the tumor entity but also their interactions
with endothelial and stromal components [32–34]. Ex-
pression of N-cadherin is further increased in tumors
with metastatic potential and is up-regulated in many
cancers, including breast invasive ductal carcinomas
[24, 34, 35], colorectal cancers [36, 37], esophageal
squamous cell carcinomas [21], and non-small cell
lung cancers [38].
Vimentin, an important component of the cytoskel-
eton, is widely distributed in mesenchymal cells such as
endothelial cells, lymphocytes, and fibroblasts [25, 39].
As another well-known marker of EMT, several studies
have shown that the abnormal expression of vimentin
was present in many kinds of epithelial tumors and asso-
ciated with the invasion and metastasis of cancer cells
[40, 41]. Furthermore, the overexpression of vimentin in
breast cancer cells is correlated with poor prognosis,
leading to adverse clinicopathological features in patients
[39, 42]. EMT is known as a cadherin switching process,
leading to primary molecular changes, including the loss
of epithelial cell markers and overexpression of mesen-
chymal cell markers [43–45].
In the present study, we confirmed that the expression
of E-cadherin was down-regulated, and that the expres-
sion of N-cadherin and vimentin was up-regulated in
PGCCs with budding daughter cells. By detecting EMT-
related proteins in cancer cell lines, we estimate that the
migration and invasion ability of the daughter cells bud-
ded from PGCCs could be attributed to EMT. Further-
more, more PGCCs were detected in the group of breast
Fig. 8 Expression of E-cadherin, N-cadherin, and vimentin in single stroma PGCCs of human breast cancer. a Single stroma PGCC in human breast
cancer with lymph node metastasis (Black arrow head, H&E, ×200). b E-cadherin, (c) N-cadherin, (d) vimentin expression of single stroma PGCC in
human breast cancer with lymph node metastasis (Black arrow head, IHC,×200). e Single stroma PGCC in human breast cancer without metastasis
(Black arrow head, H&E, ×200). b E-cadherin, (c) N-cadherin, (d) vimentin expression of single stroma PGCC in human breast cancer
without metastasis (Black arrow head, IHC, ×200)
Table 5 The differences of E-cadherin, N-cadherin, and vimentin
expression between group III and group IV




III 52 10.90 ± 0.26 0.46 ± 0.12 0.92 ± 0.15
Benign breast
tumor
IV 11 11.64 ± 0.36 0.09 ± 0.09 0.18 ± 0.12
Z −1.246 −1.592 −2.524
P 0.213 0.111 0.012
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tumors with metastasis than in the group without me-
tastasis. Finally, expression of E-cadherin was down-
regulated, while expression of N-cadherin and vimentin
was up-regulated, in primary breast carcinomas with
metastasis and their metastatic foci, compared with pri-
mary breast carcinomas without metastasis and benign
breast lesions. These data further demonstrate that the
number of PGCCs and EMT-related protein expression
are associated with invasion and metastasis in breast
cancer. However, the mechanisms of PGCCs formation
and EMT involving in daughter cells generated by
PGCCs via budding are still unclear. Sequencing and
cGH analysis focused on the genetic heterogeneity of
PGCCs at the levels of mutation and genomic rearrange-
ments need to be performed in the future.
Conclusions
The current study introduces the novel concept that
PGCCs are present in human breast cancer, and that
PGCCs with their newly budding daughter cells contrib-
ute to the occurrence of EMT-associated cancer invasion
and metastasis. Further exploration of the mechanisms
of PGCC formation and EMT-related protein expression
in the development, invasion, and metastasis of breast
cancer is needed.
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